Sign In
Buy PTN
$11.77
+0.0500 (+0.427%)
At Close: Jun 22, 2026
Topline results expected in 1Q calendar year 2025 Study is assessing the co-administration of bremelanotide and tirzepatide on reducing body weight Data will inform and support the Company's obesity p
Data presented from clinical and preclinical studies Melanocortin agonism reduces stress signaling and resolves inflammation Potential to treat inflammatory diseases without immunosuppression CRANBURY
High selectivity for MC4R significantly reduces potential for skin pigmentation MC4R is a well-validated target for treating obesity Clinical studies with highly selective MC4R agonists targeted to c
Palatin Receives Notice of Non-Compliance from NYSE American
04:15pm, Monday, 07'th Oct 2024
CRANBURY, N.J. , Oct. 7, 2024 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the acti
Obesity: Phase 2 Clinical Study with Melanocortin-4 Receptor (MC4R) Agonist plus Glucagon Like Peptide-1 (GLP-1) Patient Dosing Commenced 3Q Calendar Year 2024 Patient Enrollment Expected to be Comple
Palatin to Report Fourth Quarter and Fiscal Year End 2024 Results
07:30am, Thursday, 26'th Sep 2024
Teleconference and Webcast to be held on October 1, 2024 CRANBURY, N.J. , Sept. 26, 2024 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN) will announce its fourth quarter and fiscal yea
Palatin Provides Update on Clinical Programs, Strategic Priorities, and Anticipated Milestones
07:30am, Monday, 09'th Sep 2024
Dry Eye Disease (DED): PL9643 MELODY-2 & MELODY-3 Phase 3 Pivotal Clinical Studies FDA Confirms Protocols and Endpoints Targeting Enrollment Start in 4Q Calendar Year 2024 Topline Results Anticipated
FDA Confirms Acceptability of Palatin's Remaining Phase 3 Pivotal Clinical Trials for PL9643 in Dry Eye Disease (DED)
07:30am, Wednesday, 28'th Aug 2024
FDA & Palatin agree on clear regulatory path for PL9643 NDA submission in DED FDA confirms acceptability of protocols and endpoints for remaining MELODY-2 & MELODY-3 Phase 3 Pivotal Clinical Trials in
Complete enrollment currently expected in 3Q 2024 Topline results expected in 1Q calendar year 2025 Additional studies under assessment for multiple metabolic conditions CRANBURY, N.J. , Aug. 22, 2024
Palatin Announces Exercise of Warrants for Approximately $6.1 Million Gross Proceeds
08:00am, Friday, 21'st Jun 2024
CRANBURY, N.J. , June 21, 2024 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN) ("Palatin" or the "Company"), a biopharmaceutical company developing first-in-class medicines based on mo
In ED patients that do not respond to PDE5i monotherapy ~30-40% of ED patients do not respond to PDE5i treatment Data from this Phase 2 clinical study is expected by end of calendar year 2024 Publishe
Palatin Initiates Phase 2 Clinical Study of Bremelanotide for the Treatment of Obesity
07:30am, Wednesday, 12'th Jun 2024
Co-Administration Phase 2 study of bremelanotide with tirzepatide (GLP-1) to provide key information for melanocortin treatments of obesity Topline data expected by end of calendar year 2024 Additiona
Palatin Technologies Upgraded to Buy: What Does It Mean for the Stock?
03:17pm, Monday, 20'th May 2024
Investors might want to bet on The sole determinant of the Zacks rating is a company's changing earnings picture. The Zacks Consensus Estimate -- the consensus of EPS estimates from the sell-side anal
Palatin Reports Third Quarter Fiscal Year 2024 Financial Results and Provides Corporate Update
07:30am, Wednesday, 15'th May 2024
Positive Phase 3 PL9643 MELODY-1 Pivotal Study Results Co-Primary Symptom Endpoint of Pain Met Statistical Significance (P
Palatin to Report Third Quarter Fiscal Year 2024 Results; Teleconference and Webcast to be held on May 15, 2024
07:30am, Thursday, 09'th May 2024
CRANBURY, N.J. , May 9, 2024 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN) will announce its third quarter fiscal year 2024 operating results on Wednesday, May 15, 2024, before the o
